AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Plains All American Pipeline misses revenue but beats earnings in Q3 2024. Learn why PAA stock offers strong yield and ...

Trump's potential economic policies include tariffs, deregulation, and immigration reforms, which could impact inflation, job ...

Lumine Group is focused on acquiring and optimizing TMT software companies. Learn why LMGIF stock is a Hold for now, despite ...

Financial writer recommends holding Johnson Controls due to unstable financials, restructuring uncertainties, and regulatory ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Grupo Financiero Galicia is benefiting from a rebound in private sector lending activity in Argentina. Market forecasts see ...

Nextracker boasts strong fundamentals, including high profit margins, double-digit revenue growth, and a solid balance sheet, ...

Based on the table, the company's average revenue growth is primarily driven by the increase in crude oil transportation ...

Vale (NYSE:VALE) -3.6% in Monday's trading as UBS downgrades shares to Neutral from Buy with an $11.50 price target, cut from ...

Boeing's preferred stock offers a 5.6% yield with dividends paid quarterly starting January 2025. Read why mandatory ...

Global Net Lease has a Dividend Payout ratio of 150% and has negative 72% price returns since IPO. Read our full bear case ...